Horizon Discovery Enters Chinese Clinical Diagnostics Market
News Nov 17, 2016
Horizon Discovery Group has announced that it has entered into partnerships with three leading Chinese diagnostic kit developers. Under the terms of the agreements, Horizon will provide HDx Reference Standards for novel Next Generation Sequencing (NGS) assay development, clinical trials, and ultimately for inclusion as in-kit controls under Original Equipment Manufacturer (OEM) agreements.
Under these agreements, Horizon will support the development of new NGS diagnostic assays that, upon approval by the Chinese FDA, will be used to identify which patients would benefit from receiving novel targeted therapies to treat solid and liquid tumours.
The developers will initially pay Horizon for Reference Standards for use as quality controls in their assay development and clinical trial programmes, with typical revenues expected from each programme in the mid- to high five figure (sterling) range.
Assays in China are under obligation by the Chinese FDA not to make any changes in the format of the test for a period of five years from approval, and so Horizon is in discussions with each developer to provide Reference Standards as in-kit controls for a minimum of five years post-clearance. Cleared assays under such agreements would provide Horizon with expected revenues in the six figure (sterling) range per annum. Each developer is anticipated to develop three to four assays per year over the next several years with Horizon providing Reference Standards for each. The first assays are anticipated by partners to be approved in 2018.
Based on this initial work, Horizon is now being approached for additional partnerships with the estimated 20-30 other players in a market which is among the fastest growing in the world, with strong double digit growth rates expected to reach US$ 10 Billion by 20211.
Dr. Darrin Disley, CEO, Horizon Discovery Group, commented: “Our leadership and brand reputation has allowed us to enter the important Chinese market, leading with our HDx reference standards and Bioproduction cell lines. Our dedicated emerging markets team, under the leadership of Dr. Liangshen Wei, is establishing the relationships and status necessary to succeed in this large, growing, but complex market. Today’s announcement is a validation of this effort as we establish Horizon as the preeminent provider of Reference Standards to China, initially for NGS applications and soon expanding to other genomic assays and immunohistochemistry.”
Story from Horizon Discovery. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
New Blood Test Could Help Distinguish Heart Attack from Heart StrainNews
A new blood test developed by a UAlberta medical researcher is better at detecting damage to the heart caused by an actual heart attack. The test promises to improve how physicians diagnose and treat patients experiencing a possible heart attack.READ MORE
Rapid Test Helps with Administering the "Correct" DrugNews
In just three hours, a new rapid test will give information on which available antibiotic is still effective in a concrete case.READ MORE
‘Digistain’ Technology Offers Revolution in Detailed Cancer DiagnosisNews
New cutting edge technology can be used to grade cancer tumours, eradicating human subjectivity and ensuring patients get the right treatment.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018
7th International Conference on Bacteriology and Infectious Diseases
Jun 04 - Jun 05, 2018